간질 진단 시장 - 전략적 인사이트와 예측(2026-2035년)

The Epilepsy Diagnostics Market is anticipated to grow at a CAGR of 9.6% from USD 8.29 billion in 2026 to USD 18.88 billion in 2035.

The global epilepsy diagnostics market is undergoing a significant transformation, driven by technological advancements and a growing emphasis on early and accurate diagnosis. This market encompasses a comprehensive range of medical devices, imaging systems, molecular diagnostic tests, wearable monitoring technologies, and clinical software. Healthcare providers are increasingly adopting a multimodal diagnostic approach, integrating electroencephalography (EEG), neuroimaging, and genetic testing to improve diagnostic confidence across diverse patient populations. The rising global burden of epilepsy, affecting approximately 50 million people worldwide, is creating sustained demand for advanced diagnostic solutions. Artificial intelligence is reshaping clinical workflows by automating EEG interpretation and supporting neurologists in emergency settings. These structural changes, coupled with national neurological strategies and expanding reimbursement for neurodiagnostic procedures, position epilepsy diagnostics as a critical component of modern neurological care.

Market Drivers

Rising Global Burden of Epilepsy Is Expanding Diagnostic Demand

• Epilepsy remains one of the world's most common neurological disorders, creating sustained demand for accurate diagnostic evaluation. Healthcare providers are expanding diagnostic capacity because earlier identification reduces treatment delays and improves long-term seizure management. Clinical pathways increasingly depend on objective neurophysiological evidence before initiating long-term antiseizure therapy. Hospitals are investing in modern EEG infrastructure to support growing neurological workloads. These developments reinforce sustained demand for comprehensive epilepsy diagnostics.

AI-Assisted EEG Interpretation Is Transforming Clinical Workflow

• Electroencephalography remains the foundation of epilepsy diagnosis because it directly records abnormal cerebral electrical activity. Growing patient volumes are increasing pressure on neurologists responsible for interpreting prolonged EEG recordings. Manufacturers are integrating machine-learning algorithms that automatically identify seizure patterns and prioritize clinically significant recordings. Healthcare institutions are adopting these platforms to improve workflow efficiency and accelerate treatment decisions. Automated EEG interpretation strengthens diagnostic consistency while supporting specialist shortages in high-demand neurological settings. Recent FDA clearances for AI-enabled seizure detection software illustrate this technological progression.

Expansion of Precision Medicine Is Increasing Molecular Diagnostic Adoption

• Genetic understanding of epilepsy continues to influence diagnostic practice because inherited epileptic syndromes require targeted clinical management. Neurologists increasingly incorporate molecular testing into comprehensive diagnostic pathways for pediatric and complex epilepsy cases. Diagnostic laboratories are expanding genomic testing capabilities to identify pathogenic variants associated with treatment response and disease prognosis. Earlier molecular diagnosis supports personalized therapeutic decisions and family counseling. Precision diagnostics therefore represent an increasingly important component of modern epilepsy care.

Growth of Critical Care Neurology Is Supporting Continuous EEG Monitoring

• Intensive care units frequently manage patients with altered consciousness where seizures remain clinically silent. Continuous EEG monitoring is becoming standard practice for many high-risk neurological patients because bedside observation alone often fails to detect non-convulsive seizure activity. Hospitals are deploying portable monitoring systems that enable rapid neurological assessment within emergency and critical care environments. Earlier seizure identification improves treatment timing while reducing neurological complications. This clinical evolution continues to expand demand for portable EEG platforms and automated monitoring solutions.

Market Restraints

• High acquisition and maintenance costs of advanced neurodiagnostic equipment limit adoption among smaller hospitals and resource-constrained healthcare systems. Limited availability of trained epileptologists and EEG technologists restricts efficient utilization of sophisticated diagnostic technologies. Variability in reimbursement policies for advanced neuroimaging, prolonged EEG monitoring, and genetic testing slows widespread clinical adoption. Additionally, the complexity of integrating new diagnostic technologies with existing hospital information systems can present operational hurdles.

Technology and Segment Insights

By Product

• Electroencephalography (EEG) systems form the foundation of epilepsy diagnosis, directly measuring abnormal electrical activity associated with epileptic seizures. Demand is increasing as hospitals expand continuous EEG monitoring to improve detection of focal and non-convulsive seizures. Manufacturers are integrating artificial intelligence and automated waveform analysis into modern EEG platforms. Portable and wireless EEG systems are supporting broader adoption across emergency departments and outpatient neurology clinics. Magnetic resonance imaging (MRI) remains essential for identifying structural brain abnormalities, while computed tomography (CT), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) provide complementary functional and anatomical information. Magnetoencephalography (MEG) offers advanced localization capabilities for presurgical evaluation. Molecular and genetic diagnostic tests are becoming increasingly important for identifying inherited epileptic syndromes. Wearable and ambulatory monitoring devices are enabling extended patient observation outside traditional hospital environments.

By Diagnostic Technology

• Neuroimaging plays a fundamental role in epilepsy diagnosis by identifying structural and functional brain abnormalities that contribute to seizure disorders. Demand is increasing as clinicians rely on high-resolution imaging to localize epileptogenic lesions, particularly in drug-resistant epilepsy patients. Hospitals are expanding access to advanced MRI, PET, and SPECT technologies to support comprehensive presurgical evaluations. Electrophysiological diagnostics, including routine and continuous EEG, remain the cornerstone of epilepsy diagnosis. Molecular diagnostics are gaining prominence for identifying genetic causes and supporting personalized treatment strategies. Digital and AI-based diagnostics are emerging as transformative technologies, automating seizure detection and improving interpretation efficiency.

By Epilepsy Type

• Focal epilepsy represents the largest diagnostic segment because seizures originate within a specific brain region and often require detailed localization before treatment decisions. Neurologists are utilizing multimodal diagnostic approaches to accurately identify seizure onset zones, particularly in patients with drug-resistant epilepsy who may benefit from surgical intervention. Healthcare providers are combining prolonged EEG monitoring with high-resolution MRI, PET, and MEG to improve localization accuracy. Generalized epilepsy, combined generalized and focal epilepsy, and epilepsy of unknown type represent additional segments requiring comprehensive diagnostic evaluation.

By End User

• Hospitals represent the largest end-user segment, driven by the need for comprehensive diagnostic services and continuous monitoring capabilities. Neurology clinics are expanding access to EEG and ambulatory monitoring services. Diagnostic imaging centers provide specialized neuroimaging services. Academic and research institutions contribute to innovation and clinical validation of emerging technologies. Ambulatory surgical centers are adopting portable monitoring solutions for outpatient procedures.

Competitive and Strategic Outlook

• The competitive landscape features established medical technology companies and specialized neurodiagnostic firms. GE HealthCare combines advanced diagnostic imaging, artificial intelligence, and digital healthcare solutions within an integrated neurological imaging ecosystem. Siemens Healthineers differentiates itself through leadership in advanced neuroimaging technologies and AI-enabled clinical workflows. Koninklijke Philips N.V. maintains a strong position through its comprehensive portfolio of diagnostic imaging systems and connected healthcare solutions. Nihon Kohden Corporation specializes in neurophysiological monitoring technologies, particularly EEG systems. Natus Medical Incorporated focuses on neurodiagnostic and neurological monitoring solutions. Compumedics Limited provides specialized EEG and long-term monitoring technologies. Cadwell Industries, Inc. offers electrophysiological diagnostic systems for neurology and epilepsy laboratories. Masimo Corporation is expanding digital health capabilities that support neurological assessment in acute care environments.
• Strategic developments include increasing integration of artificial intelligence into diagnostic platforms, expansion of cloud-based neurology solutions, and development of portable monitoring technologies for decentralized epilepsy care. Companies are forming partnerships with healthcare institutions and research organizations to validate emerging technologies and accelerate commercialization. The market is shifting toward integrated diagnostic ecosystems that combine hardware, software, and digital health services into scalable, interoperable platforms.

Conclusion

• The epilepsy diagnostics market is poised for substantial growth, driven by the rising global burden of epilepsy, technological advancements in AI and precision medicine, and increasing emphasis on early diagnosis. The shift toward integrated diagnostic ecosystems combining electrophysiological monitoring, neuroimaging, molecular diagnostics, and AI-powered analytics is reshaping clinical practice. Manufacturers are focusing on portable, interoperable, and intelligent solutions that address specialist shortages and improve healthcare access. Companies that successfully combine diagnostic hardware, intelligent software, and digital health services are expected to strengthen their market position. Ongoing regulatory support and investments in neurological infrastructure across emerging economies will further accelerate innovation and market adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Epilepsy Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Epilepsy Disease Overview
• 3.3 Evolution of Epilepsy Diagnostics
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Classification
• 3.8 Epidemiology and Prevalence Analysis
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Diagnostic Pathway and Clinical Workflow
• 3.11 Current Diagnostic Landscape and Unmet Clinical Needs

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Diagnostic Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Artificial Intelligence Integration in Epilepsy Diagnostics
• 6.6 Digital Health Integration
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Epilepsy Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Diagnostic Modality
• 8.3 Analysis by Biomarker Type
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by Testing Methodology

9. Global Epilepsy Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Electroencephalography (EEG) Systems
  • 9.1.2 Magnetic Resonance Imaging (MRI)
  • 9.1.3 Computed Tomography (CT)
  • 9.1.4 Positron Emission Tomography (PET)
  • 9.1.5 Single-Photon Emission Computed Tomography (SPECT)
  • 9.1.6 Magnetoencephalography (MEG)
  • 9.1.7 Molecular & Genetic Diagnostic Tests
  • 9.1.8 Wearable and Ambulatory Monitoring Devices
• 9.2 By Diagnostic Technology
  • 9.2.1 Neuroimaging
  • 9.2.2 Electrophysiological Diagnostics
  • 9.2.3 Molecular Diagnostics
  • 9.2.4 Digital & AI-Based Diagnostics
• 9.3 By Epilepsy Type
  • 9.3.1 Focal Epilepsy
  • 9.3.2 Generalized Epilepsy
  • 9.3.3 Combined Generalized and Focal Epilepsy
  • 9.3.4 Unknown Epilepsy
• 9.4 By Age Group
  • 9.4.1 Pediatric
  • 9.4.2 Adult
  • 9.4.3 Geriatric
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Neurology Clinics
  • 9.5.3 Diagnostic Imaging Centers
  • 9.5.4 Academic & Research Institutes
  • 9.5.5 Ambulatory Surgical Centers

10. Global Epilepsy Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Epilepsy Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 GE HealthCare
• 13.2 Siemens Healthineers AG
• 13.3 Koninklijke Philips N.V.
• 13.4 Nihon Kohden Corporation
• 13.5 Natus Medical Incorporated
• 13.6 Compumedics Limited
• 13.7 Cadwell Industries, Inc.
• 13.8 Masimo Corporation
• 13.9 EGI (Electrical Geodesics, Inc.)
• 13.10 Neurosoft
• 13.11 Micromed S.p.A.
• 13.12 CERIBELL, Inc.
• 13.13 Medtronic plc
• 13.14 Canon Medical Systems Corporation
• 13.15 Fujifilm Healthcare Corporation

14. Global Epilepsy Diagnostics Market Commercial Forecast Analysis

• 14.1 Electroencephalography (EEG) Systems
• 14.2 Magnetic Resonance Imaging (MRI)
• 14.3 Computed Tomography (CT)
• 14.4 Positron Emission Tomography (PET)
• 14.5 Single-Photon Emission Computed Tomography (SPECT)
• 14.6 Magnetoencephalography (MEG)
• 14.7 Molecular & Genetic Diagnostic Tests
• 14.8 Wearable and AI-Enabled Epilepsy Monitoring Solutions

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends